文献速递姑息放疗与转移瘤放疗物理与技术

立体定向消融放疗治疗寡转移性癌症的多中心2期试验初步结果

Initial Results of a Multicenter Phase 2 Trial of Stereotactic Ablative Radiation Therapy for Oligometastatic Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-08-25

该多中心前瞻性2期试验于2011至2017年纳入147例寡转移(1-5个转移灶)癌症患者,采用立体定向消融放疗(SABR),中位随访41.3个月,中位总生存42.3个月,5年总生存43%,5年局部无进展生存74%、远处无进展生存17%,急性3级以上毒性2.0%、晚期3级以上毒性1.4%,患者报告生活质量在治疗完成时及6周、3个月、9个月无显著变化,6个月和12个月时显著改善。

要点

  • 147例寡转移癌症患者接受SABR,中位随访41.3个月,中位总生存42.3个月(95%CI 27.4-∞),5年总生存43%。
  • 5年局部无进展生存74%,5年远处无进展生存17%。
  • 急性2级以上和3级以上毒性分别为7.5%和2.0%,晚期2级以上和3级以上毒性均为1.4%。

核心结论

  • 该多中心前瞻性2期研究显示,SABR治疗复发性寡转移癌症是可行且可耐受的治疗选择,急性及晚期3级毒性极小,患者报告生活质量未受到不良影响。

研究设计与样本

  • 多中心前瞻性2期试验,2011年至2017年前瞻性招募147例寡转移(1-5个转移灶)癌症患者,SABR剂量和分次取决于病灶大小和位置,随访在SABR完成后6周内及之后每3个月进行,采用反向Kaplan-Meier法计算中位随访时间。

主要发现

  • 中位年龄66.4岁(四分位距59.9-74.6),最常见原发肿瘤为肺(21.8%,非小细胞n=29、小细胞n=3)、结直肠腺癌(21.1%)和头颈(10.9%,鳞状细胞癌n=11)。
  • 中位随访41.3个月(四分位距14.6-59.0),中位总生存42.3个月(95%CI 27.4-∞),5年总生存43%。
  • 5年局部无进展生存74%,5年远处无进展生存17%。
  • 急性2级以上和3级以上毒性分别为7.5%和2.0%,晚期2级以上和3级以上毒性均为1.4%。
  • 治疗完成时及治疗后6周、3个月、9个月生活质量无显著变化,6个月和12个月时患者报告生活质量有统计学显著改善。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Oligometastatic disease has emerged as a potentially curable state in the spectrum of cancer progression. Aggressive local therapy such as stereotactic ablative radiation therapy (SABR) may improve oncologic outcomes. Herein, we report the initial oncologic outcomes and patient-reported quality of life (PR-QoL) from a phase 2 multicenter trial for patients with oliogmetastatic disease. METHODS AND MATERIALS: Patients with oligometastatic disease (1-5 metastases) were prospectively recruited between 2011 and 2017. SABR dose and fractionation was dependent on the lesion size and location. Patient follow-up occurred within 6 weeks of completion of SABR and at 3-month intervals. Patients received a Functional Assessment of Cancer Therapy-General questionnaire at baseline and at each follow-up to assess for PR-QoL. Median follow-up was calculated by reverse Kaplan-Meier method. Overall survival (OS), local progression-free survival, and distant progression-free survival were calculated using the Kaplan-Meier method. RESULTS: We enrolled 147 patients with oligometastatic cancer with a median age of 66.4 years (interquartile range, 59.9-74.6). The most common primary tumors included lung (21.8%, non-small cell: n = 29, small cell: n = 3), colorectal adenocarcinoma (21.1%), and head and neck (10.9%, squamous cell carcinoma: n = 11). In a median follow-up of 41.3 months (interquartile range: 14.6-59.0), the median OS was 42.3 months (95% confidence interval: 27.4-∞) with 5-year OS of 43%. Five-year local progression-free survival and distant progression-free survival were 74% and 17%, respectively. Acute grade 2+ and 3+ toxicity were 7.5% and 2.0%, respectively, and late grade 2+ and 3+ toxicity were both 1.4%. There was no significant change in quality of life at completion and 6 weeks, 3 months, and 9 months after treatment. At 6 and 12 months, patients were found to have statistically significant improvement in PR-QoL. CONCLUSIONS: This multicenter prospective phase 2 study demonstrates that SABR for recurrent oligometastatic cancer is a feasible and tolerable treatment option with minimal acute and late grade 3 toxicity. Additionally, PR-QoL was not adversely affected.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Sutera P, Clump DA, Kalash R, et al. Initial Results of a Multicenter Phase 2 Trial of Stereotactic Ablative Radiation Therapy for Oligometastatic Cancer. Int J Radiat Oncol Biol Phys. 2018. PMID: 30149056. doi:10.1016/j.ijrobp.2018.08.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。